Sutro Biopharma: Multi-cancer opportunity for FolRa-targeting ADC Luvelta

Sutro Biopharm is hosting an investor webcast highlighting the significant potential of luveltamab tazevibulin, luvelta, a novel folate receptor-alpha or FolRalpha targeting ADC. “The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRalpha-expressing cancers, including platinum-resistant ovarian cancer , endometrial cancer, CBF/GLIS; RAM phenotype RAM phenotype acute myeloid leukemia , and non-small cell lung cancer NSCLC. “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile. We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer. “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRalpha expression, which could double the current eligible patient population relative to the FolRalpha-targeting ADC on the market. In 2024, we look forward to advancing two synergistic registrational clinical trials for luvelta in ovarian cancer and CBF/GLIS AML, while continuing to progress the development of additional indications.”